RootsAnalysis is pleased to announce the publication of its recent study, titled, “Blood-BrainBarrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive DrugDelivery Technology Platforms and Therapeutics.”
The report features anextensive study of the current market landscape, offering an informed opinionon the likely adoption of BBB penetration technologies and affiliated drugs,over the next decade. The report features an in-depth analysis, highlightingthe diverse capabilities of stakeholders engaged in this domain. In addition toother elements, the study includes:
· An overview of the overall landscape of BBBpenetration technologies, featuring an in-depth analysis of the technologiesbased on a number of parameters
· A detailed assessment of the current marketlandscape of BBB penetrant drugs.
· Identification of contemporary market trends,depicted using three schematic representations, which include [A] a tree maprepresentation, [B] a bubble analysis and [C] an informative heptagonrepresentation.
· An insightful competitiveness analysis of BBBpenetration technologies, taking into consideration the supplier power and keytechnology specific information.
· Elaborate profiles of prominent technologydevelopers that are engaged in the development of at least four drugs.
· An analysis of the partnerships that havebeen established in the domain, in the period between 2014 and 2020.
· An elaborate discussion on the dealstructures of various types of technology licensing agreements inked in thisdomain.
· An analysis of the investments made in thedomain, in the period between 2014 and 2020 (till March).
· An in-depth analysis of the various patentsthat have been filed / granted related to BBB penetration technologies, tillNovember 2019.
· An insightful chessboard analysishighlighting the most preferred / popular drug development strategies / pathsadopted by majority of the drug developers (with clinical candidates) in orderto progress their lead drug candidates.
· An assessment of the most commonly targeteddisorders affecting the CNS, shortlisted on the basis of number of BBBpenetrant drugs in development.
· A list of 240+ drug developers targetingAlzheimer’s disease and Parkinson’s disease that are likely to partner with BBBpenetration technology providers.
· A case study highlighting the workingprinciple of the most common approaches that are being employed for thedevelopment of BBB penetration technologies.
· An informative analysis of contemporaryGoogle Trends in the time period between 2015 and 2019 (till December) andinsights generated from recent news articles related to the BBB, indicating theincreasing popularity of this domain.
Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below)
Getan Exclusive PDF Sample: https://www.rootsanalysis.com/reports/310/request-sample.html
Typeof Payment Model Adopted
· Upfront payments
· Milestone payments
Typeof Molecule
· Small Molecules
· Biologics
TargetDisease Indication
· Brain Metastases in Breast Cancer
· Glioblastoma Multiforme
· Hunter Syndrome
· Hurler Syndrome
LeadingTechnology Platforms
· G®-Technology
· J-Brain Cargo® Technology
· LRP-1 Technology
· Trojan Horse Technology
LeadingDrug Developers
· 2-BBB
· Angiochem
· ArmaGen
· JCR Pharmaceuticals
KeyGeographical Regions
· North America
· Europe
· Asia-Pacific
Transcriptsof interviews held with the following senior level representatives ofstakeholder companies
· Ram Bhatt (Chief Executive Officer, Chairmanand Founder, Innovative California Biosciences International (ICBI))
· Frank S Walsh (Chief Executive Officer andFounder, Ossianix)
· Pieter Gaillard (Chief Executive Officer andCo-Founder, 2-BBB)
· Rob Hutchison (Chief Executive Officer andChairman, biOasis Technologies)
· Mathias Schmidt (Chief Executive Officer,ArmaGen)
· Mark L Peterson (Chief Operating Officer,Cyclenium Pharma)
· Xavier Rivero (Chief Operating Officer,Sagetis Biotech)
· Carole Desseaux (Head of Clinical Affairs,CarThera)
· Jamal Temsamani (Head of Drug Development,Vect-Horus)
· Kevin Kit Parker (Professor, Wyss Institute,Harvard University)
Requestfor Customization:
https://www.rootsanalysis.com/reports/310/request-customization.html
AboutRoots Analysis
RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
PleaseVisit Our Upcoming Reports
Gonorrhea:Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
LactoseIntolerance: Pipeline Review, Developer Landscape and Competitive Insights,2021-2031
ColdChain Logistics Market, Industry Trends and Global Forecasts, 2021-2030
